Latest:
The Rapid Reporter: April 2007
This month we report on presentations made at the BIO (Biotechnology Industry Organization)CEO & Investor Conference (February 11-14, 2007, New York, NY).
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
By Eileen Koutnik-Fotopoulos
Latest:
Integrative Medicine and Cancer Treatment
Linda A. Lee, MD, director of the Johns Hopkins Integrative Medicine & Digestive Center (JHIMDC) in Lutherville, Maryland, believes that an integrative approach to treating conditions and symptoms helps improve patients' quality of life.
By Elizabeth Freid Vocke
Latest:
Are Your Patients in Clinical Trials? US Oncology Surveys Oncologists
Participation in clinical trial research is essential to continued improvement in cancer care. Yet, fewer than 10% of U.S. adults enroll in trials. A recent US Oncology�sponsored survey found that most
oncologists remain optimistic about the future of clinical trial research. We discuss obstacles to clinical trial enrollment with Nicholas Vogelzang, MD, and Matthew Galsky, MD, of the Comprehensive CancerCenters of Nevada.
By Elizabeth Mills
Latest:
The Virtual Window: Clinical Trial Reports--March 2007
Successful research into new therapies for cancer requires a ready supply of patients willing to participate in clinical trials, and physicians and other health care professionals who will refer their patients to the appropriate studies.
By Eric M. Genden, MD, Brett Miles, MD, DDS, Marshall Posner, MD
Latest:
Personalizing Treatment for HPV-Related Head and Neck Cancer
Over the past decade, it has become apparent that head and neck squamous cell carcinoma-including cancers of the mouth, throat, and larynx-is actually two separate diseases.
By Gina Columbus
Latest:
Findings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALL
Low disease burden prior to treatment with CD19-specific chimeric antigen receptor T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia.
By Heidi D. Klepin, MD, MS
Latest:
Predicting Treatment Outcomes in Older Adults With AML
Measurable patient characteristics that predict better tolerance have not been widely studied and are desperately needed in clinical practice to inform treatment decision-making and individualize care for each older adult with AML.
By James Barnes
Latest:
Staying Focused in Turbulent Times
When the market is volatile, people think about their financial future. With current market events as turbulent as they are, you
may be concerned about their potential impact on your 401(k) account. During times like this, it is more important than ever to follow certain basic, time-tested principles of investing.
By Jane de Lartigue, PhD
Latest:
SABCS Studies Highlight Promise and Complexity in Targeting PI3K in Breast Cancer
Although there is a significant scientific rationale for targeting the PI3K pathway in breast cancer, research findings presented recently at the 2014 San Antonio Breast Cancer Symposium (SABCS) highlight the inherent complexities in using agents directed at this cell-signaling network.
By Jason Broderick
Latest:
Scientists Closer to Effectively Using Cord Blood to Treat Patients with Cancer
Scientists at Fred Hutchinson Cancer Research Center in Seattle, Washington, successfully tested a mechanism that increases the number of progenitor cells extracted from a unit of human umbilical cord blood. The laboratory method potentially solves the 1- to 2-month delay in myeloid engraftment after cord blood transplantation (CBT).
By Jeffrey J. Wargo, MD, Laurel L. Northouse, PhD, Ann M. Schafenacker, RN,and A. Mark Fendrick, MD
Latest:
Lack of Discontinuation of Statin Therapy After Diagnosis of End-Stage Cancer
The diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.
By John A. Zoidis, MD
Latest:
Pegylated Liposomal Doxorubicin (Doxil) and Drug Combinations in Multiple Myeloma
Current treatment approaches for mutiple myeloma focus on improving progression-free and overall survival. Although five-year survival rates have increased significantly over the past ten years, the prognosis of the disease is generally poor. The availability of several promising new therapies offers clinicians treatment options to further improve response rates, especially through the development of new combination regimens.
By John D. Zoidis, MD
Latest:
BIO-BUZZ: Inhibition of Angiogenesis with Bevacizumab Shows Promise in the Treatment of Recurrent or Advanced Non%u2013Small-Cell Lung Cancer
This year in the US, the American Cancer Society estimates that lung cancer will kill more people than breast, prostate, colon, liver, and kidney cancers combined, making it the leading cause of cancer death among Americans.